Porous silicon confers bioactivity to polycaprolactone composites in vitro

Journal of Materials Science: Materials in Medicine

Volumn 25, Issue 4, 2014, Pages 1087-1097

  Henstock, J R ^a   Ruktanonchai, U R ^b   Canham, L T ^c   Anderson, S I ^d  

^a KEELE UNIVERSITY   (United Kingdom)

^b NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

^c pSiMedica Ltd   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MATERIALS; BIOMATERIALS; DEGRADATION; DRUG DELIVERY; OSTEOBLASTS; PHOSPHATASES; PHOSPHATE MINERALS; SILICATES; SILICON; TISSUE ENGINEERING;

ALKALINE PHOSPHATASE ACTIVITY; EMERGING APPLICATIONS; FIRST ORDER REACTIONS; OSTEOBLAST PROLIFERATION; PRIMARY HUMAN OSTEOBLASTS; PROPORTIONAL RELATIONSHIPS; SILICON-SUBSTITUTED HYDROXYAPATITES; SIMULATED BODY FLUIDS;

POROUS SILICON;

ALKALINE PHOSPHATASE; BIOMATERIAL; CALCIUM PHOSPHATE; COLLAGEN; HYDROXYAPATITE; POLYCAPROLACTONE; SILICIC ACID; SILICON; BONE PROSTHESIS; POLYESTER;

ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; BODY FLUID; CELL CULTURE; CELL PROLIFERATION; COMPOSITE MATERIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEGRADATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; OSTEOBLAST; POROSITY; PRIORITY JOURNAL; TENSILE STRENGTH; ANIMAL; BIOMECHANICS; BONE PROSTHESIS; CELL LINE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; MACROPHAGE ACTIVATION; MATERIALS TESTING; METABOLISM; TISSUE ENGINEERING;

MURINAE;

ALKALINE PHOSPHATASE; ANIMALS; BIOCOMPATIBLE MATERIALS; BIOMECHANICAL PHENOMENA; BONE SUBSTITUTES; CALCIUM PHOSPHATES; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; MACROPHAGE ACTIVATION; MATERIALS TESTING; MICE; OSTEOBLASTS; POLYESTERS; POROSITY; SILICIC ACID; SILICON; TISSUE ENGINEERING;

EID: 84897068466     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-014-5140-5     Document Type: Article

References (41)

1. Carlisle EM. Silicon as an essential element. Fed Proc. 1974;33:1758-66.
2. Carlisle EM. Silicon as a trace nutrient. Sci Total Environ. 1988;73:95-106.
3. Reffitt DM, Ogston N, Jugdaohsingh R, Cheung HFJ, Evans BAJ, Thompson RPH, Powell JJ, Hampson GN. Orthosilicic acid stimulates collagen type 1 synthesis and osteoblastic differentiation in human osteoblast-like cells in vitro. Bone. 2003;32:127-35. (Pubitemid 36299140)
4. Arumugam MQ, Ireland DC, Brooks RA, Rushton N, Bonfield W. Orthosilicic acid increases collagen type I mRNA expression in human bone-derived osteoblasts in vitro. Key Eng Mater. 2006;254:869-72.
5. Anderson SI, Downes S, Perry CC, Caballero AM. Evaluation of the osteoblast response to a silica gel in vitro. J Mater Sci Mater Med. 1998;9:731-5. (Pubitemid 29043279)
6. Xynos IE, Alasdair JE, Buttery LDK, Hench LL, Polak JM. Gene-expression profiling of human osteoblasts following treatment with the ionic products of Bioglass 45S5. J Biomed Mater Res. 2001;55:151-7. (Pubitemid 32198497)
7. Valerio P, Pereira MM, Goes AM, Leite MF. The effect of ionic products from bioactive glass dissolution on osteoblast proliferation and collagen production. Biomaterials. 2004;25:2941-8. (Pubitemid 38210187)
8. Sripanyakorn S, Jugdaohsingh R, Thompson RPH, Powell JJ. Dietary silicon and bone health. Nutr Bull. 2005;30:222-30. (Pubitemid 41726078)
9. Jugdaohsingh R, Tucker KL, Qiao N, Cupples LA, Kiel DP, Powell JJ. Dietary silicon intake is positively associated with bone mineral density in men and premenopausal women of the Framingham Offspring cohort. J Bone Miner Res. 2004;19:297-307. (Pubitemid 38116744)
10. Hench LL. The story of Bioglass®. J Mater Sci. 2006;17:967-78.
11. Canham T. Bioactive silicon fabrication via nanoetching techniques. Adv Mater. 1995;7:1033-7.
12. Anglin EJ, Cheng L, Freeman WR, Sailor MJ. Porous silicon in drug delivery devices and materials. Adv Drug Deliv Rev. 2008;60:1266-77.
13. Serda RE, Gu J, Bhavane RC, Liu X, Chiappini C, Decuzzi P, Ferrari M. The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials. 2009;30:2440-8.
14. Zhang K, Loong SL, Connor S, Yu SW, Tan SY, Ng RT, Lee KM, Canham L, Chow PK. Complete tumor response following intratumoral 32P BioSilicon on human hepatocellular and pancreatic carcinoma xenografts in nude mice. Clin Cancer Res. 2005;11:7532-7. (Pubitemid 41507715)
15. Park JH, Gui L, Malzahn G, Ruoslahti E, Bhatia SN, Sailor MJ. Biodegradable porous silicon nanoparticles for in vivo applications. Nat Mater. 2009;8:331-6.
16. Coffer JL, Montchamp JL, Aimone JB, Weis RP. Routes to calcifled porous silicon: implications for drug delivery and biosensing. Physica Status Solidi A. 2003;197:336-9.
17. Anglin EJ, Schwartz MP, Ng VP, Perelman LA, Sailor MJ. Engineering the chemistry and nanostructure of porous silicon Fabry-Pérot films for loading and release of a steroid. Langmuir. 2004;20:11264-9.
18. Charnay C, Begu S, Tourne-Peteilh C, Nicole L, Lerner DA, Devoisselle JM. Inclusion of ibuprofen in mesoporous templated silica: drug loading and release property. Eur J Pharm Biopharm. 2004;57:533-40. (Pubitemid 38490572)
19. Vaccari L, Canton D, Zaffaroni N, Villa R, Tormen M, di Fabrizio E. Porous silicon as drug carrier for controlled delivery of doxorubicin anticancer agent. Microelectron Eng. 2006;83:1598-601.
20. Salonen J, Kaukonen AM, Hirvonen J, Lehto V-P. Mesoporous silicon in drug delivery applications. J Pharm Sci. 2008;97:632-53. (Pubitemid 351293873)
21. Whitehead MA, Fan D, Mukherjee P, Akkaraju GR, Canham LT, Coffer JL. High-porosity poly(epsilon-caprolactone)/mesoporous silicon scaffolds: calcium phosphate deposition and biological response to bone precursor cells. Tissue Eng Part A. 2008;14:195-206. (Pubitemid 351520430)
22. Johansson F, Kanje M, Linsmeier CE, Wallman L. The influence of porous silicon on axonal outgrowth in vitro. IEEE Trans Biomed Eng. 2008;55:1447-9. (Pubitemid 351440487)
23. Alvarez SD, Derfus AM, Schwartz MP, Bhatia SN, Sailor MJ. The compatibility of hepatocytes with chemically modified porous silicon with reference to in vitro biosensors. Biomaterials. 2008;30:26-34.
24. Dash TK, Konkimalla VB. Poly-E-caprolactone based formulations for drug delivery and tissue engineering: a review. J Control Release. 2012;158:15-33.
25. Sinha VR, Trehan A. Development, characterization, and evaluation of ketorolac tromethamine-loaded biodegradable microspheres as a depot system for parenteral delivery. Drug Deliv. 2008;15:365-72.
26. Rohner D, Hutmacher DW, Cheng TK, Oberholzer M, Hammer B. In vivo efficacy of bone-marrow-coated polycaprolactone scaffolds for the reconstruction of orbital defects in the pig. J Biomed Mater Res B. 2003;66:574-80. (Pubitemid 37517131)
27. Halimaoui A. Porous silicon formation by anodization. In: Canham LT, editor. Properties of porous silicon. London: Institution of Engineering and Technology; 1997.
28. Kokubo T, Kushitani H, Sakka S, Kitsugi T, Yamamuro T. Solutions able to reproduce in vivo surface-structure changes in bioactive glass-ceramic A-W. Biomed Mater Res. 1990;24:721-34. (Pubitemid 20236523)
29. Chouzouri G, Xanthos M. In vitro bioactivity and degradation of polycaprolactone composites containing silicate fillers. Acta Biomater. 2007;3:745-56. (Pubitemid 47209500)
30. Venugopal JR, Low S, Choon AT, Kumar AB, Ramakrishna S. Nanobioengineered electrospun composite nanofibers and osteoblasts for bone regeneration. Artif Organs. 2008;32:388-97. (Pubitemid 351677402)
31. Porter AE, Patel N, Skepper JN, Best SM, Bonfield W. Comparison of in vivo dissolution processes in hydroxyapatite and silicon-substituted hydroxyapatite bioceramics. Biomaterials. 2003;24:4609-20. (Pubitemid 37013622)
32. Porter AE, Patel N, Skepper JN, Best SM, Bonfield W. Effect of sintered silicate-substituted hydroxyapatite on remodelling processes at the bone-implant interface. Biomaterials. 2004;25:3303-14. (Pubitemid 38234791)
33. Gibson IR, Best SM, Bonfield W. Effect of silicon substitution on the sintering and microstructure of hydroxyapatite. J Am Ceram Soc. 2002;85:2771-7. (Pubitemid 35465676)
34. Schwarz K. A bound form of silicon in glycosaminoglycans and polyuronides. Proc Natl Acad Sci. 1973;70:1608-12.
35. Kleveta G, Borzȩcka K, Zdioruk M, Czerkies M, Kuberczyk H, Sybirna N, et al. LPS induces phosphorylation of actin-regulatory proteins leading to actin reassembly and macrophage motility. J Cell Biochem. 2012;113:80-92.
36. Scotchford CA, Garle MJ, Batchelor J, Bradley J, Grant DM. Use of a novel carbon fibre composite material for the femoral stem component of a THR system: in vitro biological assessment. Biomaterials. 2003;24:4871-9. (Pubitemid 37188667)
37. Keeting PE, Oursler MJ, Weigand KE, Bonde SK, Spelsberg TC, Riggs BL. Zeolite A increases proliferation, differentiation and transforming growth factor beta production in normal adult human osteoblast-like cells in vitro. J Bone Miner Res. 1992;7:1281-9. (Pubitemid 23000968)
38. Sammons RL, El Haj AJ, Marquis PM. Novel culture procedure permitting the synthesis of proteins by rat calvarial cells cultured on hydroxyapatite particles to be quantified. Biomaterials. 1994;15:536-42. (Pubitemid 24180622)
39. Homaeigohar SSh, Shokrgozar MA, Sadi AY, Khavandi A, Javadpour J, Hosseinalipour M. In vitro evaluation of biocompatibility of beta-tricalcium phosphate-reinforced high-density polyethylene; an orthopedic composite. J Biomed Mater Res A. 2005;75:14-22. (Pubitemid 41298183)
40. Kubo K, Tsukasa N, Uehara M, Izumi Y, Ogino M, Kitano M, Sueda T. Calcium and silicon from bioactive glass concerned with formation of nodules in periodontal-ligament fibroblasts in vitro. J Oral Rehabil. 1997;24:70-5. (Pubitemid 127732064)
41. Zhou H, Choong P, McCarthy R, Chou ST, Martin TJ, Ng KW. In situ hybridization to show sequential expression of osteoblast gene markers during bone formation in vivo. J Bone Miner Res. 1994;9:1489-99. (Pubitemid 24268862)